Cybin Inc Stock Price, News & Analysis

Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, achieved significant milestones as outlined in a December 2020 agreement. This includes a payment of $2,033,309.79 to Adelia shareholders, tied to milestone achievements. Class B shares will be issued, exchangeable for Cybin common shares at a rate of 10 to 1. The process for exchange is scheduled over the next two years. Cybin continues its mission to develop safe therapeutics to address mental health issues, leveraging innovative drug discovery and delivery systems.

Cybin has launched the EMBARK Psychedelic Facilitator Training Program, led by a team of 28 experts, aiming to enhance the training of psychedelic-assisted psychotherapy facilitators. This comprehensive program emphasizes ethical education and prepares facilitators to handle diverse participant experiences through six clinical domains and four care cornerstones. The initiative reflects Cybin's commitment to advancing therapeutic practices in the psychedelic field and supporting mental health treatment. The company continues to focus on psychedelic health innovations.

Cybin Inc. has published a peer-reviewed article detailing EMBARK, a model of psychedelic-assisted psychotherapy aimed at improving treatment effectiveness for mental health issues. Published on June 2, 2022, in Frontiers in Psychology, the article outlines EMBARK's six clinical domains: Existential-Spiritual, Mindfulness, Body Aware, Affective-Cognitive, Relational, and Keeping Momentum. The model responds to existing gaps in psychedelic therapy, integrating evidence-based practices and ethical considerations. Upcoming clinical trials will utilize EMBARK to support study participants using proprietary psychedelic molecules CYB003 and CYB004.

Cybin Inc. will host a Key Opinion Leader webinar on June 9, 2022, from 11:00 a.m. ET to 12:00 p.m. ET. Featured speakers include renowned experts Dr. John Krystal from Yale School of Medicine and Dr. David Nutt from Imperial College London, who will discuss the evolving psychedelics landscape and emerging therapeutic options. The event, moderated by Doug Drysdale, Cybin's CEO, aims to shed light on the potential of psychedelic-based treatments for mental health disorders. Registration is available on Cybin's website.

Cybin has submitted an Investigational New Drug (IND) application to the FDA for its CYB003, a deuterated psilocybin analog, aiming to treat major depressive disorder (MDD). This milestone follows successful IND-enabling work, with expectations to initiate Phase 1/2a clinical trials in mid-2022. The trial is a randomized, double-blind, placebo-controlled study that will assess the rapid onset of antidepressant effects and safety. Preliminary pharmacokinetic and safety data are expected by year-end 2022.

Cybin Inc. will participate in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. As the first psychedelics company listed on the NYSE since August 5, 2021, Cybin is committed to transforming mental health treatments through innovative psychedelic therapies. Following the ceremony, in-person meetings with institutional investors will occur on May 18 and 19 in New York City. For inquiries, contact Cybin Investor Relations.

Cybin Inc. (NYSE American: CYBN) has announced that CEO Doug Drysdale will participate in a fireside chat during the H.C. Wainwright Global Investment Hybrid Conference from May 23-26, 2022, at Fontainebleau Miami Beach. The live webcast of the chat is scheduled for May 25, 2022, at 12:30 p.m. ET. Interested listeners can access the event through the company's investor relations website.

Cybin focuses on developing psychedelics into therapeutics, working with a network of partners to create effective treatments for mental health challenges.

Cybin Inc. and Kernel announce positive pilot results from a feasibility study utilizing Kernel's Flow technology to assess neuro-effects of ketamine. Conducted over 11 days, the study confirmed changes in functional connectivity consistent with existing research. Results will be presented at the PSYCH Symposium in London on May 11, 2022. This study, which received FDA Investigational New Drug authorization, paves the way for advancements in psychedelic therapeutics, highlighting the potential of real-time brain activity measurement.

Cybin announced that its deuterated psilocybin analog, CYB003, will be presented at the 'From Research to Reality' Global Summit on Psychedelic-Assisted Therapies, scheduled for May 27-29, 2022, in Toronto. The abstract, titled Pharmacological and Pharmacokinetic Profile of CYB003, indicates that CYB003 may offer therapeutic benefits over traditional psilocybin, including improved dosing accuracy and tolerability. Cybin aims to advance treatment options for mental health disorders through its innovative drug development strategies.